Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Denali Therapeutics (DNLI) Total Current Liabilities (2017 - 2025)

Denali Therapeutics (DNLI) has disclosed Total Current Liabilities for 9 consecutive years, with $98.4 million as the latest value for Q4 2025.

  • Quarterly Total Current Liabilities fell 3.77% to $98.4 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $98.4 million through Dec 2025, down 3.77% year-over-year, with the annual reading at $98.4 million for FY2025, 3.77% down from the prior year.
  • Total Current Liabilities for Q4 2025 was $98.4 million at Denali Therapeutics, up from $90.1 million in the prior quarter.
  • The five-year high for Total Current Liabilities was $391.1 million in Q1 2023, with the low at $51.4 million in Q2 2021.
  • Average Total Current Liabilities over 5 years is $164.0 million, with a median of $90.6 million recorded in 2025.
  • The sharpest move saw Total Current Liabilities soared 577.2% in 2022, then plummeted 80.26% in 2023.
  • Over 5 years, Total Current Liabilities stood at $378.2 million in 2021, then decreased by 3.79% to $363.9 million in 2022, then crashed by 78.57% to $78.0 million in 2023, then surged by 31.07% to $102.2 million in 2024, then decreased by 3.77% to $98.4 million in 2025.
  • According to Business Quant data, Total Current Liabilities over the past three periods came in at $98.4 million, $90.1 million, and $91.1 million for Q4 2025, Q3 2025, and Q2 2025 respectively.